Arne G Schwindt1, J Gray Bennett2, William H Crowder2, Suhail Dohad3, Sean F Janzer4, Jon C George5, Barry Tedder6, Thomas P Davis7, Ian M Cawich8, Roger S Gammon9, Patrick E Muck10, John P Pigott11, Dwight A Dishmon12, Lou A Lopez13, Jaafer A Golzar14, Jack R Chamberlin15, Michael J Moulton16, Ramzan M Zakir17, Amir K Kaki18, Gary J Fishbein19, Huey B McDaniel20, Ayala Hezi-Yamit21, John B Simpson21,22, Arjun Desai21,23. 1. 1 Department of Vascular Surgery, St Franziskus-Hospital Münster, Germany. 2. 2 St Dominic-Jackson Memorial Hospital, Jackson, MI, USA. 3. 3 Cedars Sinai Medical Center, West Hollywood, CA, USA. 4. 4 Einstein Medical Center, Philadelphia, PA, USA. 5. 5 Deborah Heart and Lung Center, Brown Mills, NJ, USA. 6. 6 St Bernards Medical Center, Jonesboro, AR, USA. 7. 7 St John Hospital and Medical Center, Detroit, MI, USA. 8. 8 Arkansas Heart Hospital, Little Rock, AR, USA. 9. 9 Heart Hospital of Austin, TX, USA. 10. 10 Good Samaritan Hospital, Cincinnati, OH, USA. 11. 11 Jobst Vascular Institute Promedica Toledo Hospital, Toledo, OH, USA. 12. 12 Methodist South Hospital, Memphis, TN, USA. 13. 13 St Joseph's Hospital, Fort Wayne, IN, USA. 14. 14 Advocate Christ Hospital and Medical Center, Oak Lawn, IL, USA. 15. 15 Alexian Brothers Medical Center, Elk Grove Village, IL, USA. 16. 16 University of Nebraska Medical Center, Omaha, NE, USA. 17. 17 St Peters University Hospital, New Brunswick, NJ, USA. 18. 18 DMC Cardiovascular Institute Harper-Hutzel Hospital, Detroit, MI, USA. 19. 19 Good Samaritan Hospital, Dayton, OH, USA. 20. 20 Coastal Vascular and Interventional, Pensacola, FL, USA. 21. 21 Avinger Inc, Redwood City, CA, USA. 22. 22 Sequoia Hospital, Redwood City, CA, USA. 23. 23 Stanford University Medical Center, Stanford, CA, USA.
Abstract
PURPOSE: To evaluate the safety and efficacy of a novel optical coherence tomography (OCT)-guided atherectomy catheter in treating patients with symptomatic femoropopliteal disease. METHODS: The VISION trial ( ClinicalTrials.gov identifier NCT01937351) was a single-arm, multicenter, global investigational device exemption study enrolling 158 subjects (mean age 67.2±10.5 years; 87 men) across 20 participating sites. In this cohort, 198 lesions were treated with an average length of 53±40 mm using the Pantheris catheter alone or Pantheris + adjunctive therapy. The primary safety endpoint was the composite of major adverse events (MAEs) through 6 months (objective performance goal 43.2%). Technical success (primary efficacy outcome) was defined as the percent of target lesions with a residual diameter stenosis ≤50% after treatment with the Pantheris device alone (objective performance goal 87.0%). Procedural success was defined as reduction in stenosis to ≤30% after Pantheris ± adjunctive therapy. Tissue specimens retrieved from each treated lesion were histologically analyzed to evaluate the accuracy and precision of OCT image guidance. RESULTS: The primary efficacy outcome was achieved in 192 (97.0%) of the 198 lesions treated with the Pantheris catheter. Across all lesions, mean diameter stenosis was reduced from 78.7%±15.1% at baseline to 30.3%±11.8% after Pantheris alone (p<0.001) and to 22.4%±9.9% after Pantheris ± adjunctive therapy (p<0.001). Of the 198 target lesions, 104 (52.5%) were treated with the Pantheris alone, 84 (42.4%) were treated with Pantheris + adjunctive angioplasty, and 10 (5.1%) with Pantheris + angioplasty + stenting. The composite MAE outcome through 6 months occurred in 25 (16.6%) of 151 subjects. There were no clinically significant perforations, 1 (0.5%) catheter-related dissection, 4 (2%) embolic events, and a 6.4% clinically driven target lesion revascularization rate at 6 months. The 40-lesion chronic total occlusion (CTO) subset (mean lesion length 82±38 mm) achieved a similar significant reduction in stenosis to 35.5%±13.6% after Pantheris alone (p<0.001). Histological analysis of atherectomy specimens confirmed <1% adventitia in 82.1% of the samples, highlighting the precision of OCT guidance. Characterization of the OCT-guided lesions revealed evidence of an underestimation of disease burden when using fluoroscopy. CONCLUSION: OCT-guided atherectomy for femoropopliteal disease is safe and effective. Additionally, the precision afforded by OCT guidance leads to greater removal of plaque during atherectomy while sparing the adventitia.
PURPOSE: To evaluate the safety and efficacy of a novel optical coherence tomography (OCT)-guided atherectomy catheter in treating patients with symptomatic femoropopliteal disease. METHODS: The VISION trial ( ClinicalTrials.gov identifier NCT01937351) was a single-arm, multicenter, global investigational device exemption study enrolling 158 subjects (mean age 67.2±10.5 years; 87 men) across 20 participating sites. In this cohort, 198 lesions were treated with an average length of 53±40 mm using the Pantheris catheter alone or Pantheris + adjunctive therapy. The primary safety endpoint was the composite of major adverse events (MAEs) through 6 months (objective performance goal 43.2%). Technical success (primary efficacy outcome) was defined as the percent of target lesions with a residual diameter stenosis ≤50% after treatment with the Pantheris device alone (objective performance goal 87.0%). Procedural success was defined as reduction in stenosis to ≤30% after Pantheris ± adjunctive therapy. Tissue specimens retrieved from each treated lesion were histologically analyzed to evaluate the accuracy and precision of OCT image guidance. RESULTS: The primary efficacy outcome was achieved in 192 (97.0%) of the 198 lesions treated with the Pantheris catheter. Across all lesions, mean diameter stenosis was reduced from 78.7%±15.1% at baseline to 30.3%±11.8% after Pantheris alone (p<0.001) and to 22.4%±9.9% after Pantheris ± adjunctive therapy (p<0.001). Of the 198 target lesions, 104 (52.5%) were treated with the Pantheris alone, 84 (42.4%) were treated with Pantheris + adjunctive angioplasty, and 10 (5.1%) with Pantheris + angioplasty + stenting. The composite MAE outcome through 6 months occurred in 25 (16.6%) of 151 subjects. There were no clinically significant perforations, 1 (0.5%) catheter-related dissection, 4 (2%) embolic events, and a 6.4% clinically driven target lesion revascularization rate at 6 months. The 40-lesion chronic total occlusion (CTO) subset (mean lesion length 82±38 mm) achieved a similar significant reduction in stenosis to 35.5%±13.6% after Pantheris alone (p<0.001). Histological analysis of atherectomy specimens confirmed <1% adventitia in 82.1% of the samples, highlighting the precision of OCT guidance. Characterization of the OCT-guided lesions revealed evidence of an underestimation of disease burden when using fluoroscopy. CONCLUSION: OCT-guided atherectomy for femoropopliteal disease is safe and effective. Additionally, the precision afforded by OCT guidance leads to greater removal of plaque during atherectomy while sparing the adventitia.
Authors: Ramya C Mosarla; Ehrin Armstrong; Yonatan Bitton-Faiwiszewski; Peter A Schneider; Eric A Secemsky Journal: J Soc Cardiovasc Angiogr Interv Date: 2022-08-20
Authors: Adam Janas; Krzysztof Milewski; Piotr Buszman; Aleksandra Kolarczyk-Haczyk; Wojciech Trendel; Maciej Pruski; Wojciech Wojakowski; Paweł Buszman; Radosław S Kiesz Journal: Postepy Kardiol Interwencyjnej Date: 2020-04-03 Impact factor: 1.426
Authors: Bethany G Wardle; Graeme K Ambler; Rami W Radwan; Robert J Hinchliffe; Christopher P Twine Journal: Cochrane Database Syst Rev Date: 2020-09-29
Authors: Maaz Bj Syed; Alexander J Fletcher; Rachael O Forsythe; Jakub Kaczynski; David E Newby; Marc R Dweck; Edwin Jr van Beek Journal: Br J Radiol Date: 2019-09-10 Impact factor: 3.039